Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [ 18F]fluorodeoxyglucose positron emission tomography and computed tomography

Human Gene Therapy

Volumn 23, Issue 1, 2012, Pages 91-97

  Sze, Daniel Y ^a   Iagaru, Andrei H ^a   Gambhir, Sanjiv S ^a   De Haan, Hans A ^b   Reid, Tony R ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MediGene   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ONCOLYTIC HERPES VIRUS;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE ESCALATION; FATIGUE; FEVER; HERPES VIRUS; HUMAN; LIVER METASTASIS; MALE; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIMPLEXVIRUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

HERPESVIRIDAE;

EID: 84855866162     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.141     Document Type: Article

References (20)

1. Barwick, T., Bencherif, B., Mountz, J.M., and Avril, N. (2009). Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl. Med. Commun. 30, 908-917.
2. Benjamin, R.S., Choi, H., Macapinlac, H.A., et al. (2007). We should desist using RECIST, at least in GIST. J. Clin. Oncol. 25, 1760-1764. (Pubitemid 46797958)
3. Breitbach, C.J., De Silva, N.S., Falls, T.J., et al. (2011). Targeting tumor vasculature with an oncolytic virus. Mol. Ther. 19, 886-894.
4. Chang, J.F., Chen, P.J., Sze, D.Y., et al. (2009). Oncolytic vir-otherapy for advanced liver tumours. J. Cell. Mol. Med. 13, 1238-1247.
5. Forner, A., Ayuso, C., Varela, M., et al. (2009). Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115, 616-623.
6. Geevarghese, S.K., Geller, D.A., de Haan, H.A., et al. (2010). Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum. Gene Ther. 21, 1119-1128.
7. Gotthardt, M., Bleeker-Rovers, C.P., Boerman, O.C., and Oyen, W.J. (2010). Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J. Nucl. Med. 51, 937-949.
8. Kelly, K.J., Wong, J., and Fong, Y. (2008). Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin. Investig. Drugs 17, 1105-1113.
9. Kemeny, N., Brown, K., Covey, A., et al. (2006). Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum. Gene Ther. 17, 1214-1224. (Pubitemid 44975138)
10. Kuruppu, D., Dorfman, J.D., and Tanabe, K.K. (2007). HSV-1 viral oncolysis and molecular imaging with PET. Curr. Cancer Drug Targets 7, 175-180. (Pubitemid 46348632)
11. Lencioni, R., and Llovet, J.M. (2010). Modified RECIST (mRE-CIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60.
12. Mittra, E.S., Goris, M.L., Iagaru, A.H., et al. (2011). Pilot phar-macokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging avb3 integrin levels. Radiology 260, 182-191.
13. Pysz, M.A., Gambhir, S.S., and Willmann, J.K. (2010). Molecular imaging: current status and emerging strategies Clin. Radiol. 65, 500-516.
14. Reid, T., Galanis, E., Abbruzzese, J., et al. (2002). Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070-6079. (Pubitemid 35244455)
15. Riaz, A., Memon, K., Miller, F.H., et al. (2011). Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J. Hepatol. 54, 695-704.
16. Stanford, M.M., Bell, J.C., and Vähä-Koskela, M.J. (2010). Novel oncolytic viruses: riding high on the next wave? Cytokine Growth Factor Rev. 21, 177-183.
17. Sze, D.Y., Freeman, S.M., Slonim, S.M., et al. (2003). Intraarterial adenovirus for metastatic gastrointestinal cancer: activity, ra-diographic response, and survival. J. Vasc. Interv. Radiol. 14, 279-290. (Pubitemid 36314756)
18. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 92, 205-216. (Pubitemid 30099779)
19. Yamamoto, S., Deckter, L.A., Kasai, K., et al. (2006). Imaging immediate-early and strict-late promoter activity during on-colytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther. 13, 1731-1736. (Pubitemid 44849038)
20. Young, H., Baum, R., Cremerius, U., et al. (1999). Measurement of clinical and subclinical tumour response using [18F]-fluor-odeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35, 1773-1782. (Pubitemid 29512308)